AbCellera Biologics (ABCL)

• Market cap: $1.72B
• 1 day: -11.77%
• 5 days: -8.02%
• 1 month: 20.6%
• 3 months: 56.55%
• 6 months: 57.87%
• Year to date: 63.85%
• 1 year: 137.13%
• 5 years: -78.57%
• 10 years: -90.46%
• Sector: Healthcare
• Industry: Biotechnology

About: AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Employees: 562